The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     
 


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sandau, M. M.
Right arrow Articles by Jameson, S. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sandau, M. M.
Right arrow Articles by Jameson, S. C.
The Journal of Immunology, 2004, 173: 6537-6541.
Copyright © 2004 by The American Association of Immunologists


CUTTING EDGE

Cutting Edge: Transpresentation of IL-15 by Bone Marrow-Derived Cells Necessitates Expression of IL-15 and IL-15R{alpha} by the Same Cells1

Michelle M. Sandau*, Kimberly S. Schluns2,{dagger}, Leo Lefrancois{dagger} and Stephen C. Jameson3,*

* Center for Immunology and Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, MN 55455; and {dagger} Division of Immunology, University of Connecticut Health Center, Farmington, CT 06030


    Abstract
 Top
 Abstract
 Introduction
 Materials and Methods
 Results and Discussion
 References
 
IL-15 is critical for generation of multiple lymphoid subsets. Recent data have demonstrated a unique aspect of responses to IL-15, in that cells bearing the IL-15R{alpha} chain can bind soluble IL-15 and "transpresent" the cytokine to other cells, allowing the latter to respond to IL-15. However, it is unclear whether IL-15 is normally secreted and then becomes bound to surface IL-15R{alpha} on bystander cells, or whether transpresentation is mediated by the same cells which synthesize IL-15. Using mixed bone marrow chimeric mice, we present evidence for the latter model, showing that development of NK cells and memory phenotype CD8 T cells necessitates that both IL-15 and IL-15R{alpha} be expressed by the same population of cells. These data argue that soluble forms of IL-15 are irrelevant for physiological responses to this cytokine, and the implications of this finding are discussed.


    Introduction
 Top
 Abstract
 Introduction
 Materials and Methods
 Results and Discussion
 References
 
Interleukin 15 is critical for the development and/or survival of memory CD8 T cells, NK cells, NK-T cells, and certain intestinal intraepithelial lymphocytes (1). Three proteins, IL-15R{alpha}, IL-2R{beta}, and common {gamma}-chain ({gamma}c),4 are involved in reactivity to IL-15. Accordingly, mice deficient in any of the three receptor chains, or in IL-15 itself, exhibit defects in development of the lymphocyte subsets discussed above (1, 2, 3).

Recent reports suggest a unique mechanism of IL-15 recognition. Cells bearing the IL-15R{alpha} chain, which binds IL-15 with high affinity, can "transpresent" the cytokine to bystander cells expressing the {gamma}c and IL-2R{beta} chains, allowing the latter cells to functionally respond to IL-15 (4). Transpresentation appears to dominate in vivo, in that cells expressing all three components of the IL-15R are unable to be maintained in an environment where bystander cells lack IL-15R{alpha}, while, conversely, cells lacking the IL-15R{alpha} chain can develop and be maintained providing bystander cells transpresent IL-15 (5, 6).

A simple model of transpresentation might be that secreted IL-15 in the serum or tissues becomes associated with IL-15R{alpha} chain on bystander cells, which either respond to IL-15 directly, or transpresent the cytokine to other cells. However, even cells expressing considerable levels of IL-15 mRNA secrete only low levels of IL-15 (7), suggesting free IL-15 may be rare in normal tissues. In contrast, IL-15 and IL-15R{alpha} mRNA have a broad tissue distribution and some cells, including dendritic cells and activated monocytes, express both proteins (4, 7, 8). Hence, an alternative scenario is that IL-15 transpresentation is mediated by cells which both produce IL-15 and display it bound to their own IL-15R{alpha} chain.

To test these models of transpresentation, bone marrow chimeras were produced using a mixture of IL-15–/– and IL-15R{alpha} –/– bone marrow to reconstitute an irradiated host. With conventional cytokine systems, this would lead to complementation of at least one of the bone marrow sources and thus appearance of IL-15-sensitive lymphoid populations. In contrast, however, we show that these chimeras failed to develop or sustain memory CD8 T cells and mature NK cells. These data support a model in which reactivity to IL-15 requires transpresentation by cells which coexpress IL-15 and the IL-15R{alpha} chain.


    Materials and Methods
 Top
 Abstract
 Introduction
 Materials and Methods
 Results and Discussion
 References
 
Mice

C57BL/6 (B6), B6.SJL, B6.PL, and B6.129 IL-15R{alpha} –/– mice (The Jackson Laboratory, Bar Harbor, ME) and C57BL/6 IL-15–/– (Taconic Farms, Germantown, NY) were used. In Fig. 4, IL-15–/– and IL-15R{alpha} –/– animals were >10 generations backcrossed to B6 and were derived from mice provided by J. Peschon (Immunex, Seattle, WA) and A. Ma (University of California, San Francisco, CA), respectively. OT-I TCR transgenic mice (9) were originally obtained from F. Carbone (University of Melbourne, Melbourne, Australia) and W. Heath (Walter and Eliza Hall Institute, Melbourne, Australia). All mice were maintained under specific pathogen-free conditions at the University of Minnesota or at the University of Connecticut Health Center.



View larger version (20K):
[in this window]
[in a new window]
 
FIGURE 4. Homeostasis of normal CD8 memory cells is impaired in mixed knockout chimeras. OT-I memory CD8+ T cells were CFSE labeled and transferred into the indicated bone marrow chimeric mice. Spleens cells were analyzed at 6 wk for CFSE intensity and numbers of OT-I cells (detected by OVA/Kb tetramer binding). A, CFSE intensity among OVA/Kb tetramer+CD8+ T cells (R represents the percentage of cells that proliferated). B, Absolute numbers of splenic OVA/Kb tetramer+CD8+ T cells recovered from indicated groups of chimeras.

 
Generation of bone marrow chimeras

Bone marrow cells from B6.PL (or B6.SJL), IL-15–/–, and IL-15R{alpha} –/– mice were depleted of T cells by culture, in the presence of complement, with anti-Thy1.2 (30H12) or anti-Thy1.1 (1A14) (for Figs. 1–3), or with anti-Thyl (T24; for Fig. 4). Mixed bone marrows (see Fig. 1) were injected into the tail vain of lethally irradiated (900–1000 cGy) IL-15R{alpha}–/– mice. Chimeras were used 9–12 wk later for analysis or as recipients for cell transfer.



View larger version (27K):
[in this window]
[in a new window]
 
FIGURE 1. Model of IL-15 transpresentation and experimental approach. A, Transpresentation of IL-15 involves an IL-15R{alpha}-expressing CPC. CPC may either be able to acquire soluble IL-15 produced by other cells (Model 1) or may be obliged to make their own IL-15 (Model 2). In either case, IL-15 is offered by CPC to IL-15 responder cells (which must minimally express the IL-2R{beta}-{gamma}c complex). B, Mixed bone marrow chimeras used in this study. Bone marrow from IL-15–/–, IL-15R{alpha}–/–, and congenic (either Thy1.1 or CD45.1) B6 mice was mixed in a 1:1 ratio in the combinations indicated and used to reconstitute lethally irradiated IL-15R{alpha}–/– hosts. C and D, Assessment of chimerism. C, Control (groups 1 and 2) chimeras were stained for congenic markers on bone marrow donor cells. Lymph node CD4 cells from a group 2 chimera are shown, representative of T and B cells from group 1 and 2 chimeras analyzed in two separate experiments. D, Representative staining for IL-15R{alpha} expression on cultured CD11c+CD8+ dendritic cells from control (left panel) and chimeric (right panel) animals. In this experiment, IL-15R{alpha}+ cells (determined by the indicated marker) were 31% (± 5%) and 41% (± 6%) in group 2 and 3 chimeras, respectively.

 


View larger version (30K):
[in this window]
[in a new window]
 
FIGURE 2. Memory CD8 T cell defect in mixed knockout chimeras. A, Percentage of lymph node T cells (CD4+ and CD8+) and B cells (CD19+) from chimeric and control mice. B, Memory and naive T cells were distinguished by staining for CD44 and IL-2R{beta} in the CD8+ subset (top row) and by CD45RB and IL-2R{beta} staining of the CD4+ subset (bottom row). Percentages of cells in each quadrant are given and the percentage of total CD44+CD8+ cells is underlined in the top row. C–E, Frequency of naive and memory CD8+ (C and D) and CD4+ T cells (E) based on gating shown in B. The symbols in C and E are the same as in A. D, The contribution of each donor group to naive and memory CD8 subsets are shown for group 1 and 2 chimeras. All data shown are representative of two experiments with three mice in each chimera group. Representative B6 and IL-15R{alpha}–/– controls are shown for comparison.

 


View larger version (25K):
[in this window]
[in a new window]
 
FIGURE 3. NK cells fail to develop in mixed knockout chimeras. A, NK cells from the bone marrow of chimeric and control mice. Data shown are representative of two experiments with three mice in each BM chimera group. B, Percentage of bone marrow NK cells which are Mac-1low (immature) and Mac-1high (mature) in the indicated chimeras.

 
Analysis of memory CD8 T cell proliferation in vivo

To generate memory CD8 T cells, B6 mice were adoptively transferred with OT-I TCR transgenic T cells and infected with vesicular stomatitis virus-OVA >50 days before sacrifice. Spleen cells were magnetically depleted of CD4 T cells and B cells (yielding ~85% CD8 T cell purity), labeled with CFSE and transferred, such that each recipient chimera received 9 x 106 CD8 T cells containing ~2.0 x 106 OVA/Kb tetramer+ cells. Chimeras were sacrificed 6 wk later, and splenocytes were analyzed for absolute numbers and CFSE dilution of OVA/Kb tetramer+ cells. The percentage of cells of the original population that had divided (the "responding" population, R) was calculated as described previously (10).

Flow cytometric analysis

Cells were stained with the indicated Abs (BD Pharmingen, San Diego, CA, or eBioscience, San Diego, CA) and analyzed using a FACSCalibur (BD Biosciences, San Jose, CA) and FlowJo software (TreeStar, San Carlos, CA). NK cells were identified as being CD3, NK1.1+, and (in some experiments) DX5+. In some experiments, dendritic cells were released from the spleen by treatment with 400 U/ml collagenase D (Boehringer Mannheim, Indianapolis, IN) in 10 mM EDTA (Sigma-Aldrich, St. Louis, MO), depleted of RBC, and plated overnight in 48-well plates at 5 x 106 cells/well in RPMI 1640 medium at 37°C to activate dendritic cells. Anti-IL-15R{alpha} was obtained from R&D Systems (Minneapolis, MN).


    Results and Discussion
 Top
 Abstract
 Introduction
 Materials and Methods
 Results and Discussion
 References
 
Experimental design

During transpresentation, IL-15 is bound to the IL-15R{alpha} chain on one cell (here termed a cytokine-presenting cell, or CPC) and is offered to an IL-15-responsive cell which must minimally express IL-2R{beta} and {gamma}c (Fig. 1). The CPC may bind IL-15 secreted by another cell (Fig. 1A, Model 1) or the CPC may both produce the cytokine and transpresent it, in which case the CPC must express both IL-15 and IL-15R{alpha} (Fig. 1A, Model 2). To test these opposing models, we constructed mixed bone marrow chimeras (Fig. 1B) in which bone marrow-derived cells differed in their capacity to express IL-15 and IL-15R{alpha}. In control chimeras (groups 1 and 2), congenic wild-type bone marrow was mixed in a 1:1 ratio with either IL-15–/– or IL-15R{alpha} –/–bone marrow cells. Test chimeras were generated from a 1:1 mixture of IL-15–/– and IL-15R{alpha} –/– bone marrow (mixed knockout chimeras, group 3 in Fig. 1B). In these chimeras one population could produce IL-15 but could not express the IL-15R{alpha} chain, while the other hemopoietic population could express the receptor but not the cytokine. Previous work from Schluns et al. (6) demonstrated that both bone marrow and parenchymal cells can contribute to IL-15 transpresentation. To focus on the role of IL-15 transpresentation by bonemarrow-derived cells, we used IL-15R{alpha} –/– mice as the chimera hosts (Fig. 1B).

We first tested whether both bone marrow donors had contributed to hemopoietic cells. Congenic markers (Thy-1 or CD45 alleles) distinguished donor groups in the control chimeras (groups 1 and 2). Both donors were represented in roughly equal proportions among CD4, CD8, B, and NK cells (e.g., Fig. 1C). To separate the bone marrow donor populations in the mixed knockout chimeras, we tracked expression of IL-15R{alpha}, which could be detected on cultured CD8{alpha} dendritic cells (Fig. 1D) and CD8 T cells (data not shown). By comparisonwith B6 and IL-15R{alpha}–/–, we could show that group 2 and 3 chimeras possessed both IL-15R{alpha}+ and IL-15R{alpha} cells, suggesting that both bone marrow sources contributed to the hemopoietic pool (Fig. 1D).

Mixed knockout chimeras show deficiency of CD8 memory cells

The different chimeras were compared for reconstitution of B and T cells, with unmanipulated B6 and IL-15R{alpha}–/– mice serving as a benchmark. B cells and CD4 T cells were found in equivalent percentages across all three chimera groups and were broadly similar in B6 and IL-15R{alpha}–/– controls (Fig. 2A), in keeping with a lack of IL-15 dependence for these subsets. However, a slight decrease in the percentage of CD8 T cells was found in mixed knockout (group 3) chimeras compared with control chimeras (groups 1 and 2), similar to the lower frequency of CD8 T cells in IL-15R{alpha}–/– animals. IL-15–/– and IL-15R{alpha}–/– mice show a striking deficiency of memory phenotype CD8 T cells, which is especially marked for CD8 T cells expressing CD44 and IL-2R{beta} (2, 3). Hence, we looked at the frequency of memory phenotype (CD44high) CD8 T cells, of both IL-2R{beta} low and IL-2R{beta} high subsets, in our chimeras (Fig. 2B). The percentage of cells expressing the memory marker CD44 on CD8 T cells from the control chimeras (groups 1 and 2) was similar to each other and to that of the B6 control (Fig. 2, B and C). However, the percentage of CD44high CD8 T cells in the mixed knockout chimeras was markedly lower than in control chimeras, and this deficit was even more extreme for IL-2R{beta}highCD44highCD8+ T cells (Fig. 2, B and C).

Through IL-15 transpresentation, we would expect IL-15R{alpha}–/– T cells to contribute to the memory CD8 pool in group 2 chimeras (5, 6). Indeed, by using congenic markers to distinguish donor cells, we could show that IL-15R{alpha}–/– donor cells contribute to the memory CD8 pool (Fig. 2D). In fact, we note higher frequencies of knockout CD8 memory cells than predicted by overall chimerism in both group 1 and 2 chimeras (Fig. 2D). Although the basis for this is unclear, our data nevertheless reinforce the idea that IL-15 transpresentation rescues IL-15R{alpha}–/– CD8 memory cells.

In contrast to CD8 cells, both naive (CD45RBhigh) and memory (CD45RBlow) CD4 T cells were found in similar frequencies (Fig. 2, B and E) in all three types of chimera. These data suggest that the mixed knockout chimeras were selectively deficient in generation or maintenance of CD8 memory T cells, while naive CD8 T cells and both naive and memory CD4 T cells was similar between all chimeras.

Similar patterns were observed in all of these experiments if absolute numbers rather than percentage were studied (data not shown).

Mixed knockout chimeras lack mature NK populations

Since NK cells are also IL-15 sensitive (2, 3, 11, 12), we also examined their reconstitution. The percentage of NK cells in bone marrow (Fig. 3A) was lower in all of the chimeras as compared with the B6 control, most likely due to the lack of IL-15R{alpha} on parenchymal cells in our chimeras (6). However, the mixed knockout chimeras showed a profound decrease (2- to 3-fold) in the percentage of NK cells compared with control chimeras (Fig. 3A). We went on to analyze NK cell maturation in the chimeras. Fully mature NK cells express Mac-1 ({alpha}M{beta}2 integrin), whereas their immediate precursors are Mac-1low (13). Both control chimera groups showed a discrete population of Mac-1high cells in the bone marrow, but this population was virtually absent from the mixed knockout chimeras(Fig. 3B). Immature Mac-1low NK cells were present in mixed knockout chimeras, but their frequency was about one-half that of control chimeras. These defects resemble the pattern for unmanipulated IL-15R{alpha} –/– animals (Fig. 3). Thus, mixed IL-15–/–/IL-15R{alpha} –/– bone marrow chimeras failed to develop or maintain mature NK cells. Absolute numbers of bone marrow NK cells were also affected and analogous results were observed in the spleen (data not shown).

Mixed knockout chimeras fail to support homeostasis of Ag-specific memory CD8 T cells

The homeostasis of virus-specific CD8 T cells is due to their basal proliferation in response to IL-15 (14, 15); therefore, we tested whether Ag-specific memory T cells could proliferate in mixed knockout chimeras. CFSE-labeled memory OT-I CD8 T cells were transferred into either group 1 or group 3 chimeric host mice, and their maintenance and proliferation was analyzed 6 wk later (Fig. 4). Memory CD8 T cell proliferation occurred in the control (group 1) chimeras indicated by the loss of CFSE; however, significantly fewer divisions occurred in the mixed knockout (group 3) chimeras (Fig. 4A). Furthermore, greater numbers of memory OT-I T cells persisted in group 1 vs group 3 chimeric hosts (Fig. 4B). Thus, these data reinforce the interpretation that the IL-15–/– plus IL-15Ra–/– mixed chimeras cannot support maintenance of IL-15-dependant cell types.

Overall, our data using mixed knockout chimeras support the model in which a CPC must both express IL-15R{alpha} and produce IL-15 (Fig. 1A, Model 2). The lack of complementation between the IL-15–/– and IL-15R{alpha} –/– bone marrow progenitor cells argues that cells cannot utilize secreted IL-15 for transpresentation to IL-15-dependent lymphocytes. A potential caveat with our approach would arise if IL-15 and IL-15R{alpha} expression is linked, such that deficiency of one protein influences expression of the other. However, previous reports demonstrate normal IL-15 mRNA expression in IL-15R{alpha}–/– animals (12) and our analysis reveals IL-15R{alpha} expression on IL-15–/– cells (Fig. 1D), minimizing this concern.

These data suggest IL-15 operates in a radically different manner than most cytokines, which are secreted and can act at a distance from the producing cell. rIL-15 has potent activity in vitro and in vivo (1, 3, 16), and our data do not argue against a potential therapeutic use for soluble IL-15. Rather, we propose endogenous secreted IL-15 is not sufficient for development/maintenance of IL-15-dependent hemopoietic subsets. In this model, IL-15 assumes the properties of a cell surface molecule, in that only the cells that produce the cytokine and the high-affinity receptor will be suitable CPCs. Both dendritic cells and activated monocytes coexpress IL-15 and IL-15R{alpha} (4, 8), making these cells attractive candidates for hemopoietic IL-15 CPCs.

What consequences does this mode of IL-15 presentation have for IL-15-dependent lymphocytes? If IL-15 is only transpresented by cells that express both IL-15 and IL-15R{alpha}, this offers a tight regulation of IL-15-dependent cells. For example, although memory CD8 T cells express IL-15R{alpha} (14) they appear not to produce IL-15. In a simple model of transpresentation, CD8 T cells could both respond to IL-15 and act as CPCs for other CD8 memory cells, leading to unrestrained expansion of the memory CD8 pool. However, in our current model, CPC function is confined to cells which actively synthesize the cytokine, preventing this amplifying loop. These data also reinforce the surprising conclusion that expression of IL-15R{alpha} may be irrelevant for lymphocyte reactivity to IL-15.

Overall, our data define a novel mechanism by which IL-15 is presented by bone marrow cells to lymphocytes. It will be interesting to determine whether a similar mechanism applies to other cytokines in which one receptor chain carries the majority of the ligand affinity.

Note added in proof. During review of this manuscript, similar findings were reported by Burkett et al. (Burkett, P. R., R. Koka, M. Chien, S. Chai, D. L. Boone, and A. Ma. 2004. Coordinate expression and trans presentation of interleukin (IL)-15R{alpha} and IL-15 supports natural killer cell and memory CD8+ T cell homeostasis J. Exp. Med. 200:825.).


    Acknowledgments
 
We thank Martin Prlic and members of the Jameson/Hogquist laboratories for valuable input.


    Footnotes
 
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 This work was supported by National Institutes of Health Grants AI98903 (to S.C.J.) and AI51583 and DK45260 (to L.L.). Back

2 Current address: Department of Immunology, M. D. Anderson Cancer Center, University of Texas, Houston, TX 77030. Back

3 Address correspondence and reprint requests to Dr. Stephen C. Jameson, Center for Immunology and Department of Laboratory Medicine and Pathology, University of Minnesota, MMC 334, 420 Delaware Street SE, Minneapolis, MN 55455. E-mail address: james024{at}umn.edu Back

4 Abbreviations used in this paper: {gamma}c, common {gamma}-chain; CPC, cytokine-presenting cell. Back

Received for publication August 25, 2004. Accepted for publication September 29, 2004.


    References
 Top
 Abstract
 Introduction
 Materials and Methods
 Results and Discussion
 References
 

  1. Lodolce, J., P. Burkett, R. Koka, D. Boone, M. Chien, F. Chan, M. Madonia, S. Chai, A. Ma. 2002. Interleukin-15 and the regulation of lymphoid homeostasis. Mol. Immunol. 39:537.[Medline]
  2. Lodolce, J. P., D. L. Boone, S. Chai, R. E. Swain, T. Dassopoulos, S. Trettin, A. Ma. 1998. IL-15 receptor maintains lymphoid homeostasis by supporting lymphocyte homing and proliferation. Immunity 9:669.[Medline]
  3. Kennedy, M. K., M. Glaccum, S. N. Brown, E. A. Butz, J. L. Viney, M. Embers, N. Matsuki, K. Charrier, L. Sedger, C. R. Willis, et al 2000. Reversible defects in natural killer and memory CD8 T cell lineages in interleukin 15-deficient mice. J. Exp. Med. 191:771.[Abstract/Free Full Text]
  4. Dubois, S., J. Mariner, T. A. Waldmann, Y. Tagaya. 2002. IL-15R{alpha} recycles and presents IL-15 in trans to neighboring cells. Immunity 17:537.[Medline]
  5. Burkett, P. R., R. Koka, M. Chien, S. Chai, F. Chan, A. Ma, D. L. Boone. 2003. IL-15R{alpha} expression on CD8+ T cells is dispensable for T cell memory. Proc. Natl. Acad. Sci. USA 100:4724.[Abstract/Free Full Text]
  6. Schluns, K. S., E. C. Nowak, A. Cabrera-Hernandez, L. Puddington, L. Lefrancois, H. L. Aguila. 2004. Distinct cell types control lymphoid subset development by means of IL-15 and IL-15 receptor {alpha} expression. Proc. Natl. Acad. Sci. USA 101:5616.[Abstract/Free Full Text]
  7. Bamford, R. N., A. P. Battiata, J. D. Burton, H. Sharma, T. A. Waldmann. 1996. Interleukin (IL) 15/IL-T production by the adult T-cell leukemia cell line HuT-102 is associated with a human T-cell lymphotrophic virus type I region /IL-15 fusion message that lacks many upstream AUGs that normally attenuates IL-15 mRNA translation. Proc. Natl. Acad. Sci. USA 93:2897.[Abstract/Free Full Text]
  8. Ruckert, R., K. Brandt, E. Bulanova, F. Mirghomizadeh, R. Paus, S. Bulfone-Paus. 2003. Dendritic cell-derived IL-15 controls the induction of CD8 T cell immune responses. Eur. J. Immunol. 33:3493.[Medline]
  9. Hogquist, K. A., S. C. Jameson, W. R. Heath, J. L. Howard, M. J. Bevan, F. R. Carbone. 1994. T cell receptor antagonist peptides induce positive selection. Cell 76:17.[Medline]
  10. Gudmundsdottir, H., A. D. Wells, L. A. Turka. 1999. Dynamics and requirements of T cell clonal expansion in vivo at the single-cell level: effector function is linked to proliferative capacity. J. Immunol. 162:5212.[Abstract/Free Full Text]
  11. Prlic, M., B. R. Blazar, M. A. Farrar, S. C. Jameson. 2003. In vivo survival and homeostatic proliferation of natural killer cells. J. Exp. Med. 197:967.[Abstract/Free Full Text]
  12. Koka, R., P. R. Burkett, M. Chien, S. Chai, F. Chan, J. P. Lodolce, D. L. Boone, A. Ma. 2003. Interleukin (IL)-15R{alpha}-deficient natural killer cells survive in normal but not IL-15R{alpha}-deficient mice. J. Exp. Med. 197:977.[Abstract/Free Full Text]
  13. Kim, S., K. Iizuka, H. S. Kang, A. Dokun, A. R. French, S. Greco, W. M. Yokoyama. 2002. In vivo developmental stages in murine natural killer cell maturation. Nat. Immunol. 3:523.[Medline]
  14. Schluns, K. S., K. Williams, A. Ma, X. X. Zheng, L. Lefrancois. 2002. Cutting edge: requirement for IL-15 in the generation of primary and memory antigen-specific CD8 T cells. J. Immunol. 168:4827.[Abstract/Free Full Text]
  15. Becker, T. C., E. J. Wherry, D. Boone, K. Murali-Krishna, R. Antia, A. Ma, R. Ahmed. 2002. Interleukin 15 is required for proliferative renewal of virus-specific memory CD8 T cells. J. Exp. Med. 195:1541.[Abstract/Free Full Text]
  16. Berard, M., K. Brandt, S. Bulfone-Paus, D. F. Tough. 2003. IL-15 promotes the survival of naive and memory phenotype CD8+ T cells. J. Immunol. 170:5018.[Abstract/Free Full Text]



This article has been cited by other articles:


Home page
BloodHome page
J.-s. Do and B. Min
IL-15 produced and trans-presented by DCs underlies homeostatic competition between CD8 and {gamma}{delta} T cells in vivo
Blood, June 18, 2009; 113(25): 6361 - 6371.
[Abstract] [Full Text] [PDF]


Home page
Mol Hum ReprodHome page
A. Germeyer, A. M. Sharkey, M. Prasadajudio, R. Sherwin, A. Moffett, K. Bieback, S. Clausmeyer, L. Masters, R. M. Popovici, A. P. Hess, et al.
Paracrine effects of uterine leucocytes on gene expression of human uterine stromal fibroblasts
Mol. Hum. Reprod., January 1, 2009; 15(1): 39 - 48.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
J. Rowley, A. Monie, C.-F. Hung, and T.-C. Wu
Inhibition of Tumor Growth by NK1.1+ Cells and CD8+ T Cells Activated by IL-15 through Receptor {beta}/Common {gamma} Signaling in trans
J. Immunol., December 15, 2008; 181(12): 8237 - 8247.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
S. W. Stonier, L. J. Ma, E. F. Castillo, and K. S. Schluns
Dendritic cells drive memory CD8 T-cell homeostasis via IL-15 transpresentation
Blood, December 1, 2008; 112(12): 4546 - 4554.
[Abstract] [Full Text] [PDF]


Home page
JEMHome page
E. Mortier, T. Woo, R. Advincula, S. Gozalo, and A. Ma
IL-15R{alpha} chaperones IL-15 to stable dendritic cell membrane complexes that activate NK cells via trans presentation
J. Exp. Med., May 12, 2008; 205(5): 1213 - 1225.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
C.-L. Small, S. McCormick, N. Gill, K. Kugathasan, M. Santosuosso, N. Donaldson, D. E. Heinrichs, A. Ashkar, and Z. Xing
NK Cells Play a Critical Protective Role in Host Defense against Acute Extracellular Staphylococcus aureus Bacterial Infection in the Lung
J. Immunol., April 15, 2008; 180(8): 5558 - 5568.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
A. I. Kokaji, D. L. Hockley, and K. P. Kane
IL-15 Transpresentation Augments CD8+ T Cell Activation and Is Required for Optimal Recall Responses by Central Memory CD8+ T Cells
J. Immunol., April 1, 2008; 180(7): 4391 - 4401.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
Y.-G. Lai, M.-S. Hou, Y.-W. Hsu, C.-L. Chang, Y.-H. Liou, M.-H. Tsai, F. Lee, and N.-S. Liao
IL-15 Does Not Affect IEL Development in the Thymus but Regulates Homeostasis of Putative Precursors and Mature CD8{alpha}{alpha}+ IELs in the Intestine
J. Immunol., March 15, 2008; 180(6): 3757 - 3765.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
C. Bergamaschi, M. Rosati, R. Jalah, A. Valentin, V. Kulkarni, C. Alicea, G.-M. Zhang, V. Patel, B. K. Felber, and G. N. Pavlakis
Intracellular Interaction of Interleukin-15 with Its Receptor {alpha} during Production Leads to Mutual Stabilization and Increased Bioactivity
J. Biol. Chem., February 15, 2008; 283(7): 4189 - 4199.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
S. Dubois, H. J. Patel, M. Zhang, T. A. Waldmann, and J. R. Muller
Preassociation of IL-15 with IL-15R{alpha}-IgG1-Fc Enhances Its Activity on Proliferation of NK and CD8+/CD44high T Cells and Its Antitumor Action
J. Immunol., February 15, 2008; 180(4): 2099 - 2106.
[Abstract] [Full Text] [PDF]


Home page
CVIHome page
K. U. Saikh, T. L. Kissner, S. Nystrom, G. Ruthel, and R. G. Ulrich
Interleukin-15 Increases Vaccine Efficacy through a Mechanism Linked to Dendritic Cell Maturation and Enhanced Antibody Titers
Clin. Vaccine Immunol., January 1, 2008; 15(1): 131 - 137.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
S. K. Olsen, N. Ota, S. Kishishita, M. Kukimoto-Niino, K. Murayama, H. Uchiyama, M. Toyama, T. Terada, M. Shirouzu, O. Kanagawa, et al.
Crystal Structure of the Interleukin-15{middle dot}Interleukin-15 Receptor {alpha} Complex: INSIGHTS INTO TRANS AND CIS PRESENTATION
J. Biol. Chem., December 21, 2007; 282(51): 37191 - 37204.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
A. L. Zhang, P. Colmenero, U. Purath, C. Teixeira de Matos, W. Hueber, L. Klareskog, I. H. Tarner, E. G. Engleman, and K. Soderstrom
Natural killer cells trigger differentiation of monocytes into dendritic cells
Blood, October 1, 2007; 110(7): 2484 - 2493.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
M. M. Sandau, C. J. Winstead, and S. C. Jameson
IL-15 Is Required for Sustained Lymphopenia-Driven Proliferation and Accumulation of CD8 T Cells
J. Immunol., July 1, 2007; 179(1): 120 - 125.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
N. Sato, H. J. Patel, T. A. Waldmann, and Y. Tagaya
The IL-15/IL-15R{alpha} on cell surfaces enables sustained IL-15 activity and contributes to the long survival of CD8 memory T cells
PNAS, January 9, 2007; 104(2): 588 - 593.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
X. Zhang, H. Dong, W. Lin, S. Voss, L. Hinkley, M. Westergren, G. Tian, D. Berry, D. Lewellen, R. G. Vile, et al.
Human Bone Marrow: A Reservoir for "Enhanced Effector Memory" CD8+ T Cells with Potent Recall Function
J. Immunol., November 15, 2006; 177(10): 6730 - 6737.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
T. A. Stoklasek, K. S. Schluns, and L. Lefrancois
Combined IL-15/IL-15R{alpha} Immunotherapy Maximizes IL-15 Activity In Vivo
J. Immunol., November 1, 2006; 177(9): 6072 - 6080.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
J. Ritz
Trans-presentation of IL-15
Blood, October 1, 2006; 108(7): 2135 - 2136.
[Full Text] [PDF]


Home page
BloodHome page
B. W. Blaser, N. R. Schwind, S. Karol, D. Chang, S. Shin, S. Roychowdhury, B. Becknell, A. K. Ferketich, D. F. Kusewitt, B. R. Blazar, et al.
Trans-presentation of donor-derived interleukin 15 is necessary for the rapid onset of acute graft-versus-host disease but not for graft-versus-tumor activity
Blood, October 1, 2006; 108(7): 2463 - 2469.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
S. Wei, I. Kryczek, and W. Zou
Regulatory T-cell compartmentalization and trafficking
Blood, July 15, 2006; 108(2): 426 - 431.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
M. Pelletier and D. Girard
Differential Effects of IL-15 and IL-21 in Myeloid (CD11b+) and Lymphoid (CD11b-) Bone Marrow Cells
J. Immunol., July 1, 2006; 177(1): 100 - 108.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
M. P. Rubinstein, M. Kovar, J. F. Purton, J.-H. Cho, O. Boyman, C. D. Surh, and J. Sprent
Converting IL-15 to a superagonist by binding to soluble IL-15R{alpha}
PNAS, June 13, 2006; 103(24): 9166 - 9171.
[Abstract] [Full Text] [PDF]


Home page
JEMHome page
A. Jabbari and J. T. Harty
Secondary memory CD8+ T cells are more protective but slower to acquire a central-memory phenotype
J. Exp. Med., April 17, 2006; 203(4): 919 - 932.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
A. Le Bon, V. Durand, E. Kamphuis, C. Thompson, S. Bulfone-Paus, C. Rossmann, U. Kalinke, and D. F. Tough
Direct Stimulation of T Cells by Type I IFN Enhances the CD8+ T Cell Response during Cross-Priming.
J. Immunol., April 15, 2006; 176(8): 4682 - 4689.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
G. Pulle, M. Vidric, and T. H. Watts
IL-15-Dependent Induction of 4-1BB Promotes Antigen-Independent CD8 Memory T Cell Survival.
J. Immunol., March 1, 2006; 176(5): 2739 - 2748.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
E. Mortier, A. Quemener, P. Vusio, I. Lorenzen, Y. Boublik, J. Grotzinger, A. Plet, and Y. Jacques
Soluble Interleukin-15 Receptor {alpha} (IL-15R{alpha})-sushi as a Selective and Potent Agonist of IL-15 Action through IL-15Rbeta/{gamma}: HYPERAGONIST IL-15{middle dot}IL-15R{alpha} FUSION PROTEINS
J. Biol. Chem., January 20, 2006; 281(3): 1612 - 1619.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sandau, M. M.
Right arrow Articles by Jameson, S. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sandau, M. M.
Right arrow Articles by Jameson, S. C.


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS